Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

By G. Cartron, L. Dacheux, G. Salles, P. Solal-Céligny, P. Bardos, P. Colombat, H. Watier. Blood, 2002

2,036 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/0ad0c0e324d9c8da9daa4bfd19121c0016c72713

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. A. Chan
2. P. Carter

In Molecular Biology

1. A. Chan
2. D. Baty
3. M. H. V. Van Regenmortel
4. Etienne Weiss
5. P. Carter
6. P. Chames
7. H. Rosen

In Radiology, Nuclear Medicine and Imaging

1. A. Chan
2. D. Baty
3. M. H. V. Van Regenmortel
4. Etienne Weiss
5. P. Carter
6. Mitchell R. Smith
7. P. Chames

Citations in the corpus

• Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1 (2005, background): “Rituximab-treated NHL patients that express the high affinity allele of Fc RIIIA (V158) have better prognostic outcomes than patients that solely express the low affinity allele of Fc RIIIA (F158) (36, 37).”
• Therapeutic antibodies: successes, limitations and hopes for the future (2009, positive): “Several investigators have examined the relationship between FcgR polymorphisms and clinical responses to antibody therapy (Cartron et al., 2002; Weng and Levy, 2003).”
• Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 (2003, background): “Although less efficiently, rituximab also activates Ab-dependent cellular cytotoxicity (ADCC) in vitro (3, 8), and recent evidence showing a correlation between Fc RIII polymorphisms and clinical response suggests a role for Fc RIIIbearing cells such as NK cells and macrophages in the response (12).”